よむ、つかう、まなぶ。
【参考１】新型コロナウイルス感染症COVID-19診療の手引き 第10.0版 (57 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00416.html |
| 出典情報 | 「新型コロナウイルス感染症（COVID-19）診療の手引き・第 10.0 版」の 周知について（8／21付 事務連絡）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
●新型コロナウイルス感染症（COVID-19） 診療の手引き・第 10.0 版 ●５ 薬物療法
◆引用・参考文献◆
【ガイドライン等】
• 日本感染症学会．COVID-19 に対する薬物治療の考え方 第 15.1 版．2023.2.14.
• 日本救急医学会・日本集中治療医学会．日本版敗血症診療ガイドライン 2020（J-SSCG2020）特別編，COVID-19
薬物療法に関する Rapid/Living recommendations 第 5.0 版 . 2022.7.15.
・WHO. Therapeutics and COVID-19：living guidance. 13 Jan 2023.
・NIH. Coronavirus diseases 2019（COVID-19）treatment guidelines. 20 Apr 2023.
【抗ウイルス薬】
・Bernal AJ，et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 2021.
・Davis MR，et al. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease
on haemodialysis. J Antimicrob Chemother 2021.
・Diaz GA，et al. Remdesivir and mortality in patients with COVID-19. Clin Infect Dis 2021.
・Goldman JD，et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020.
・Gottleib RL，et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2021.
・Hammond J，et al. Oral nirmatrelvir for high-risk，nonhospitalized adults with Covid-19. N Engl J Med 2022.
・Kikuchi K，et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide
cohort study. Ren Replace Ther 2021.
・Mozaffari E，et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of
in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis 2021.
・Pan H，et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 2020.
【中和抗体薬】
・Chen P，et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2020.
・Gupta A，et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J
Med 2021.
・Imai M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med 2023.
・Levin MJ, et al. Intramuscular AZD7442（tixagevimab-cilgavimab）for prevention of Covid-19. N Engl J Med 2022.
・Montgomery H, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early
outpatient treatment of COVID-19（TACKLE）: a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Respir Med 2022.
・Levin MJ, et al. AZD7442（tixagevimab-cilgavimab）for post-exposure prophylaxis of symptomatic COVID-19.
Clin Infect Dis 2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1，BA.4，and BA.5
subvariants. N Engl J Med 2022.
・Siemieniul RA，et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and
network meta-analysis. BMJ 2021.
・Weinreich DM，et al. REGN-COV2，a neutralizing antibody cocktail，in outpatients with Covid-19. N Engl J
Med 2021.
・Weinreich DM，et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J
Med 2021.
【免疫抑制・調節薬】
・Horby PW，et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020.
・Kalil AC，et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2020.
・Marconi VC，et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19（COVBARRIER）: a randomised，double-blind，parallel-group，placebo-controlled phase 3 trial. Lancet Respir Med 2021.
・RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19（RECOVERY）:
a randomized, controlled, open-label, platform trial. Lancet 2021.
・RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19（RECOVERY）:
a randomized, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022.
・WHO Rapid Evidence Appraisal for COVID-19 Therapies（REACT）Working Group. Association between
administration of IL-6 antagonists and mortality among patients hospitalized or COVID-19: A meta-analysis.
JAMA 2021.
・Stone JH，et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020.
【妊産婦に対する薬物療法】
・Burwick RM, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease
2019. Clin Infect Dis 2021.
・Garneau WM, et al. Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir
for acute SARS-CoV-2 infection. JAMA Netw Open 2022.
・Goulden B, et al. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying
anti-rheumatic drugs in utero . Rheumatology (Oxford) 2022.
◀︎ CONTENTS
57
◆引用・参考文献◆
【ガイドライン等】
• 日本感染症学会．COVID-19 に対する薬物治療の考え方 第 15.1 版．2023.2.14.
• 日本救急医学会・日本集中治療医学会．日本版敗血症診療ガイドライン 2020（J-SSCG2020）特別編，COVID-19
薬物療法に関する Rapid/Living recommendations 第 5.0 版 . 2022.7.15.
・WHO. Therapeutics and COVID-19：living guidance. 13 Jan 2023.
・NIH. Coronavirus diseases 2019（COVID-19）treatment guidelines. 20 Apr 2023.
【抗ウイルス薬】
・Bernal AJ，et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 2021.
・Davis MR，et al. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease
on haemodialysis. J Antimicrob Chemother 2021.
・Diaz GA，et al. Remdesivir and mortality in patients with COVID-19. Clin Infect Dis 2021.
・Goldman JD，et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020.
・Gottleib RL，et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2021.
・Hammond J，et al. Oral nirmatrelvir for high-risk，nonhospitalized adults with Covid-19. N Engl J Med 2022.
・Kikuchi K，et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide
cohort study. Ren Replace Ther 2021.
・Mozaffari E，et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of
in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis 2021.
・Pan H，et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 2020.
【中和抗体薬】
・Chen P，et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2020.
・Gupta A，et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J
Med 2021.
・Imai M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med 2023.
・Levin MJ, et al. Intramuscular AZD7442（tixagevimab-cilgavimab）for prevention of Covid-19. N Engl J Med 2022.
・Montgomery H, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early
outpatient treatment of COVID-19（TACKLE）: a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Respir Med 2022.
・Levin MJ, et al. AZD7442（tixagevimab-cilgavimab）for post-exposure prophylaxis of symptomatic COVID-19.
Clin Infect Dis 2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1，BA.4，and BA.5
subvariants. N Engl J Med 2022.
・Siemieniul RA，et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and
network meta-analysis. BMJ 2021.
・Weinreich DM，et al. REGN-COV2，a neutralizing antibody cocktail，in outpatients with Covid-19. N Engl J
Med 2021.
・Weinreich DM，et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J
Med 2021.
【免疫抑制・調節薬】
・Horby PW，et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020.
・Kalil AC，et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2020.
・Marconi VC，et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19（COVBARRIER）: a randomised，double-blind，parallel-group，placebo-controlled phase 3 trial. Lancet Respir Med 2021.
・RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19（RECOVERY）:
a randomized, controlled, open-label, platform trial. Lancet 2021.
・RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19（RECOVERY）:
a randomized, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022.
・WHO Rapid Evidence Appraisal for COVID-19 Therapies（REACT）Working Group. Association between
administration of IL-6 antagonists and mortality among patients hospitalized or COVID-19: A meta-analysis.
JAMA 2021.
・Stone JH，et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020.
【妊産婦に対する薬物療法】
・Burwick RM, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease
2019. Clin Infect Dis 2021.
・Garneau WM, et al. Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir
for acute SARS-CoV-2 infection. JAMA Netw Open 2022.
・Goulden B, et al. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying
anti-rheumatic drugs in utero . Rheumatology (Oxford) 2022.
◀︎ CONTENTS
57